I currently serve as Vice Chair for Research and Chief of the Radiochemistry & Imaging Sciences Service in Memorial Sloan Kettering’s Department of Radiology, and I am Director of Memorial Sloan Kettering’s Radiochemistry and Molecular Imaging Probe Core Facility. I am a Member in Memorial Sloan Kettering, head of a laboratory in the Sloan Kettering Institute’s Molecular Pharmacology Program, and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. I have published over 130 papers, books, book chapters, and reviews in the field of cancer imaging. I serve on grant review panels for the National Institutes of Health/National Cancer Institute and on a number editorial boards.
My research interests are focused on the development of new PET radiopharmaceuticals for the diagnosis and treatment of cancer. My work incorporates 89Zr, 18F, 11C, and other nonstandard nuclides, with an emphasis on designing novel PET agents for cancer imaging. My research program is a molecular-imaging-based program focused on the targetry of nonstandard nuclides as well as the development of small and biomolecule-based agents and their clinical translation. I have worked on the development of small molecules targeting cancer, as well as radiolabeled peptides and 89Zr-labeled antibodies targeting the overexpression of receptors and antigens on tumors. The research is supported by the National Institutes of Health, the Department of Education, and philanthropy.
I am also principle investigator (PI) of a “DOE Center of Excellence in Radiochemistry,” which supports junior faculty, postdoctoral, and graduate trainees. I am also a co-PI of an NSF IGERT grant with Hunter College of the City University of New York (CUNY) that will support 15 PhD candidates in radiochemistry.
- Clinical Expertise: Radiotracers; Radiochemistry
- Languages Spoken: English
- Education: PhD, Biochemistry, University of Kent (UK)
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more